Overactive Bladder
Conditions
Interventions
treatment:Sacral nerve stimulation therapy
control:Oral Tolterodine L-tartrate
Sponsors
Xiyuan Hospital, China Academy of Chinese Medical Sciences
Eligibility
Sex/Gender
All
Age
18 Years to 60 Years
Inclusion criteria
Inclusion criteria: 1) Meet the diagnostic criteria for overactive bladder, referring to the Chinese Guidelines for the Diagnosis and Treatment of Urological and Androrological Diseases (2022). 3) Female patients are 18-60 years old (including 18 years old, including 60 years old); male patients are 18-45 years old (including 18 years old, excluding 45 years old). 3) The Chinese and Western drugs used for treating OAB have not been used for nearly one week 4) Sign the informed consent form and volunteer to test.
Exclusion criteria
Exclusion criteria: Patients with urinary system infections and lower urinary tract obstruction were excluded; Patients with a neurogenic bladder were excluded; Exclude patients with urethral dysfunction; Patients with a residual urine volume of> 50ml were excluded; Excluding pregnant or lactating patients; Excluding patients with prostatic hyperplasia and prostatitis; Patients with contraindications to toterdine tartrate were excluded: urinary retention, gastric stagnation, uncontrolled Angle glaucoma, myasthenia gravis, severe ulcerative colitis, and toxic megacolon; Excluding patients with proven allergic reactions to toltrine tartrate; Patients with low renal function, autonomic neurological disease, and hiatal hernia patients were excluded; Patients with bladder outlet obstruction were excluded due to the risk of urinary retention; Due to the risk of gastric stagnation, exclude patients with gastrointestinal obstructive diseases, such as stenosis of the pyloric tract; Excluding patients who have pacemakers, alcohol and metal allergies, or are not suitable for electroacupuncture treatment; Patients who were judged by the investigator to complete the study were excluded.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| NGF;overactive bladder symptom score;BDNF; | — |
Secondary
| Measure | Time frame |
|---|---|
| Quality of life;Evaluation of the subjective efficacy of the patients; | — |
Countries
China
Contacts
Public ContactZhang Lu
Xiyuan Hospital, China Academy of Chinese Medical Sciences
Outcome results
None listed